Search

Helping to shape Europe’s clinical trials landscape: EHA selected for ACT EU advisory group

Improving the design, efficiency and effectiveness of clinical trials is the objective of the Accelerating Clinical Trials in the European Union (ACT EU) initiative.

Read more

Quality of Life and Symptoms

The goals of the SWG are:

To promote the evaluation of patient-reported outcomes (PROs) in hematology in daily clinical practice and in clinical trials.

Read more

Clinical Practice Guidelines

EHA creates clinical practice Guidelines for diagnosis and treatment of hematologic diseases. This initiative started in 2019 with the establishment of the EHA Guidelines Committee and the definition of the EHA Methodology for Guidelines.

Read more

Research

Research in hematology has dramatically improved our understanding of hematologic diseases and resulted in many innovative, groundbreaking discoveries.

Read more

EHA congratulates the Spanish Society of Hematology on its 60th anniversary

EHA President, John Gribben and member of the SEHH, María Victoria Mateos

On Thursday, June 20 the Spanish Society of Hematology (SEHH) officially celebrated its 60th anniversary with a commemorative event in Madrid.

Read more

Executive office

The EHA Board and its committees are supported by the Executive Office. An international team of staff members work in a dynamic, result-driven and open environment and takes pride in serving the association in an efficient manner.

Read more

Multiple Myeloma

The SWG Multiple Myeloma has traditionally been composed of members of the European Myeloma Network (EMN). EMN is a dedicated academic, non-profit organization for clinical research in multiple myeloma.

Read more

EU pilot on drug repurposing

Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.

Read more